Methyl 3-Aminocrotonate Bulk Price 2026 Factory Supply
- 2026 Market Outlook: Stabilized raw material costs expected to optimize bulk price tiers for large-scale API synthesis.
- Technical Specifications: Standard industrial purity exceeds 97% assay with a melting point range of 81-83 °C.
- Procurement Strategy: Direct factory supply ensures consistent COA verification and streamlined logistics for ton-scale orders.
In the landscape of pharmaceutical intermediate manufacturing, securing a reliable supply chain for critical building blocks is paramount. Methyl 3-Aminocrotonate (CAS: 14205-39-1) serves as a fundamental precursor in the synthesis of calcium channel blockers, most notably Amlodipine. As we approach 2026, procurement managers and process chemists must navigate fluctuating raw material costs and evolving quality standards. This analysis provides a technical and commercial overview of the bulk price trends, purity specifications, and strategic sourcing advantages available through direct factory supply channels.
Global Manufacturer Pricing Trends
The pricing dynamics for fine chemicals are heavily influenced by upstream petrochemical feedstocks and regional manufacturing capacity. For Methyl 3-amino-2-butenoate, the market has shown resilience against volatility due to established synthesis pathways. However, buyers must account for the total cost of ownership, which includes logistics, customs clearance, and quality assurance testing. In the 2026 forecast, prices are projected to stabilize as production efficiencies improve among leading suppliers.
A global manufacturer with integrated production facilities can offer more competitive rates compared to traders who simply repackage existing stock. The cost per kilogram decreases significantly when moving from laboratory-scale packages (e.g., 500g) to industrial drum quantities. Procurement strategies should focus on locking in long-term contracts to mitigate potential spikes in solvent costs or energy tariffs affecting the synthesis process. When evaluating the market, it is essential to distinguish between reagent-grade pricing and true industrial bulk pricing, as the latter reflects the economies of scale required for API production.
Volume Discounts for API Production
Scale-up considerations are critical when transitioning from process development to commercial manufacturing. The demand for this intermediate is driven by the consistent global requirement for cardiovascular medications. Suppliers typically structure volume discounts based on quarterly or annual commitment levels. For facilities requiring industrial purity levels consistently above 97% assay, bulk procurement offers significant margin improvements.
Logistics play a crucial role in the final landed cost. Shipping solid intermediates in lined drums or bulk bags reduces contamination risks compared to smaller bottle shipments. Furthermore, larger volumes allow for consolidated freight, reducing the per-unit shipping expense. Process chemists should verify that the bulk material maintains the same physical characteristics as smaller samples, specifically the melting point of 81-83 °C and solubility profiles in organic solvents like chloroform and acetone. Consistency in these physical parameters ensures that downstream reaction yields remain stable during scale-up.
When sourcing high-purity Methyl 3-Aminocrotonate, buyers should prioritize vendors who can demonstrate capacity for ton-scale production without compromising quality control. This ensures that the synthesis route for the final API remains robust and reproducible across different batches.
Requesting Custom COA and Quotes
Quality documentation is the cornerstone of regulatory compliance in pharmaceutical manufacturing. Every shipment must be accompanied by a comprehensive Certificate of Analysis (COA). This document should verify key parameters such as assay percentage, melting point, residual solvents, and heavy metal content. For GMP-aligned production, the ability to request custom testing protocols is a significant advantage. Some applications may require tighter specifications than the standard 97% assay, necessitating additional purification steps.
NINGBO INNO PHARMCHEM CO.,LTD. stands as a premier partner in this sector, offering transparent communication regarding technical data sheets and safety information. As a dedicated factory supply source, they facilitate direct access to production managers who can address specific technical queries regarding the organic building block stability and storage conditions. Proper storage is essential; the material should be kept in a cool, dry place away from oxidizing agents to prevent degradation of the amine functionality.
Technical Specifications Overview
To assist procurement teams in vendor qualification, the following table outlines the standard technical specifications expected for high-quality commercial supply. These metrics are derived from generalized industry standards for this CAS number.
| Parameter | Specification |
|---|---|
| Product Name | Methyl 3-Aminocrotonate |
| CAS Number | 14205-39-1 |
| Alternative Names | 3-Aminocrotonic Acid Methyl Ester, 2-Butenoic acid 3-amino methyl ester |
| Assay (Purity) | ≥ 97.0% (GC/HPLC) |
| Melting Point | 81.0 °C to 83.0 °C |
| Physical Form | Solid (White to Yellow) |
| Solubility | Insoluble in water; Soluble in chloroform and acetone |
| Molecular Formula | C5H9NO2 |
| Hazard Class | GHS Warning (Eye/Skin Irritation) |
Safety and Handling Considerations
While this intermediate is stable under normal conditions, safety data sheets indicate it causes serious eye irritation and may be harmful if swallowed. Industrial handling requires appropriate personal protective equipment, including chemical safety goggles and gloves. Ventilation systems should be in place to avoid breathing dust or vapors during the charging of reactors. Compliance with local TSCA and EINECS regulations is mandatory for international trade. Buyers should ensure their facilities are equipped to handle amine esters safely to maintain workplace safety standards.
Conclusion
Securing a stable supply of Methyl 3-Aminocrotonate for 2026 and beyond requires a partnership with a capable manufacturer who understands the nuances of API intermediate production. By focusing on industrial purity, leveraging volume discounts, and insisting on rigorous COA verification, pharmaceutical companies can optimize their production costs. NINGBO INNO PHARMCHEM CO.,LTD. provides the technical expertise and manufacturing capacity required to support large-scale operations, ensuring that your supply chain remains resilient against market fluctuations. For detailed quotes and technical consultations, direct engagement with the manufacturer is recommended to align specifications with your specific process requirements.